Evaluate the effectiveness of lopinavir/ritonavir pellets, given with two NRTIs (either zidovudine plus lamivudine or abacavir plus lamivudine), in an implementation study in infants and young children living with HIV who cannot swallow pills
current phase of drug development
updated 1 Mar 2022
In 2015, following the tentative approval by the US Federal Drug Administration of the lopinavir/ritonavir pellets developed by Cipla Ltd. (India), DNDi launched the LIVING study in five sites in Kenya to provide early access to the new formulation. The pellets are taken orally and are a significant improvement over the high-alcohol, bitter-tasting and refrigerated syrups that were previously the only available lopinavir/ritonavir formulation for young children.
The study was expanded to Uganda in 2016 and Tanzania in 2017. By December 2018, the LIVING study had enrolled 1,003 children across 12 sites in Kenya, Uganda, and Tanzania, and follow-up was completed for all sites in April 2019.
News & resources
Get our latest news, personal stories, research articles, and job opportunities.